Amedisys (NASDAQ:AMED) Rating Reiterated by Stephens

Amedisys (NASDAQ:AMED – Get Rating)‘s stock had its “equal weight” rating restated by Stephens in a report issued on Tuesday, Benzinga reports. They currently have a $103.00 target price on the health services provider’s stock. Stephens’ price objective points to a potential upside of 32.99% from the company’s previous close.

A number of other equities research analysts have also recently commented on AMED. Oppenheimer lowered their price target on shares of Amedisys from $145.00 to $125.00 and set an “outperform” rating on the stock in a report on Thursday, January 19th. StockNews.com lowered Amedisys from a “buy” rating to a “hold” rating in a research note on Friday, March 10th. SVB Leerink dropped their price objective on Amedisys from $96.00 to $85.00 and set a “market perform” rating for the company in a report on Thursday, January 5th. Benchmark reiterated a “buy” rating and issued a $115.00 price target on shares of Amedisys in a research note on Tuesday. Finally, Barclays assumed coverage on shares of Amedisys in a research report on Monday. They set an “equal weight” rating and a $93.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $119.53.

Amedisys Price Performance

AMED stock opened at $77.45 on Tuesday. The stock has a market capitalization of $2.52 billion, a PE ratio of 21.28, a price-to-earnings-growth ratio of 2.30 and a beta of 1.04. The company’s 50-day moving average is $90.18 and its 200-day moving average is $94.24. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.09 and a quick ratio of 1.09. Amedisys has a 1 year low of $76.93 and a 1 year high of $179.91.

Amedisys (NASDAQ:AMED – Get Rating) last posted its earnings results on Thursday, February 16th. The health services provider reported $1.16 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.13. Amedisys had a net margin of 5.34% and a return on equity of 15.44%. The company had revenue of $562.10 million for the quarter, compared to analyst estimates of $560.46 million. During the same quarter in the prior year, the business posted $1.18 EPS. The firm’s revenue was up .5% compared to the same quarter last year. Equities research analysts expect that Amedisys will post 4.26 EPS for the current fiscal year.

Insider Transactions at Amedisys

In related news, insider Michael Paul North sold 5,908 shares of the company’s stock in a transaction that occurred on Friday, March 3rd. The shares were sold at an average price of $86.43, for a total transaction of $510,628.44. Following the transaction, the insider now owns 4,164 shares of the company’s stock, valued at $359,894.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Amedisys

A number of hedge funds have recently made changes to their positions in the business. Signaturefd LLC increased its position in shares of Amedisys by 304.1% in the 4th quarter. Signaturefd LLC now owns 295 shares of the health services provider’s stock worth $25,000 after purchasing an additional 222 shares during the last quarter. Neo Ivy Capital Management bought a new stake in shares of Amedisys during the 2nd quarter worth $44,000. IFP Advisors Inc boosted its stake in shares of Amedisys by 331.1% during the 3rd quarter. IFP Advisors Inc now owns 569 shares of the health services provider’s stock worth $47,000 after acquiring an additional 437 shares in the last quarter. Covestor Ltd boosted its stake in shares of Amedisys by 88.9% during the 1st quarter. Covestor Ltd now owns 323 shares of the health services provider’s stock worth $56,000 after acquiring an additional 152 shares in the last quarter. Finally, Belpointe Asset Management LLC purchased a new position in shares of Amedisys during the fourth quarter valued at $57,000. Hedge funds and other institutional investors own 96.17% of the company’s stock.

Amedisys Company Profile

(Get Rating)

Amedisys, Inc engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery.